Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24670869 | 0.81 | TSHR (0.36) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL8612225 | 0.81 | TSHR (0.43) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL13850424 | 0.80 | GAA (0.39) | TSHRALDH1A1MEN1KMT2ATHRB | |
| SCHEMBL14099491 | 0.80 | EPHX2 (0.35) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL8592245 | 0.79 | CA2 (0.40) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL607318 | 0.77 | — | — | |
| SCHEMBL8404635 | 0.76 | GRIA1 (0.50) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL8404337 | 0.76 | TSHR (0.39) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL24571859 | 0.74 | ALDH1A1 (0.33) | ALDH1A1MEN1KMT2AHPGDPTGES | |
| Di(Hydroxyethyl)Ether SCHEMBL28929647 | 0.74 | TSHR (0.59) | TSHRMAPK1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002317-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-01-06 | — | — | US | disclosed |
| WO-2021263039-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | TSHR 2617/4885MAPK1 2374/4885ALDH1A1 291/4885 |
| US-20220002317-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAA1 | TSHR 1538/4885MAPK1 1464/4885ALDH1A1 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.